Agios Pharmaceuticals, Inc. AGIO
Institutional shares held
61.8 Million
297K
calls
235K
puts
Total value of holdings
$2.42B
$11.6M
calls
$9.21M
puts
Market Cap
$2.15B
54,818,000
Shares Out.
Institutional ownership
112.7%
# of Institutions
235
We take great care to ensure that the data presented and summarized in this overview for AGIOS PHARMACEUTICALS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding AGIO
View all-
Farallon Capital Management LLC San Francisco, CA5.77MShares$226 Million0.86% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.68MShares$223 Million0.0% of portfolio
-
Black Rock Inc. New York, NY4.86MShares$191 Million0.0% of portfolio
-
Bellevue Group Ag Kuesnacht, V83.59MShares$141 Million2.72% of portfolio
-
Erste Asset Management Gmb H Vienna, C42.33MShares$91.3 Million0.65% of portfolio
-
Commodore Capital LP New York, NY2.33MShares$91.3 Million7.21% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.27MShares$89.3 Million0.01% of portfolio
-
State Street Corp Boston, MA1.95MShares$76.6 Million0.0% of portfolio
-
Macquarie Group LTD Australia, C31.9MShares$74.6 Million0.08% of portfolio
-
Geode Capital Management, LLC Boston, MA1.41MShares$55.2 Million0.0% of portfolio
Latest Institutional Activity in AGIO
Top Purchases
Top Sells
About AGIO
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Insider Transactions at AGIO
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 27
2025
|
David Scadden Director |
SELL
Open market or private sale
|
Direct |
200
-1.12%
|
$8,000
$40.0 P/Share
|
|
Aug 27
2025
|
David Scadden Director |
BUY
Exercise of conversion of derivative security
|
Direct |
200
+1.11%
|
$3,600
$18.09 P/Share
|
|
Aug 11
2025
|
Cynthia Smith Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,302
+15.64%
|
-
|
|
Aug 11
2025
|
Rahul D. Ballal Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,302
+15.64%
|
-
|
|
Aug 08
2025
|
Brian Goff Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
11,085
-8.23%
|
$399,060
$36.67 P/Share
|
|
Aug 08
2025
|
Brian Goff Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
22,691
+14.42%
|
-
|
|
Jul 10
2025
|
David Scadden Director |
SELL
Open market or private sale
|
Direct |
1,400
-7.37%
|
$56,000
$40.0 P/Share
|
|
Jul 10
2025
|
David Scadden Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,400
+6.86%
|
$25,200
$18.09 P/Share
|
|
Jul 09
2025
|
Sarah Gheuens Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
11,914
-8.24%
|
$452,732
$38.34 P/Share
|
|
Jul 09
2025
|
Sarah Gheuens Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,914
+14.0%
|
$297,850
$25.01 P/Share
|
|
Jul 01
2025
|
Sarah Gheuens Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,091
-6.26%
|
$139,094
$34.17 P/Share
|
|
Jul 01
2025
|
Sarah Gheuens Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,374
+11.36%
|
-
|
|
Jun 24
2025
|
Sarah Gheuens Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,909
-4.86%
|
$95,997
$33.54 P/Share
|
|
Jun 24
2025
|
Sarah Gheuens Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+9.11%
|
-
|
|
Jun 24
2025
|
James William Burns Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
2,799
-8.9%
|
$92,367
$33.54 P/Share
|
|
Jun 24
2025
|
James William Burns Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+16.02%
|
-
|
|
Jun 24
2025
|
Brian Goff Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
18,700
-7.93%
|
$617,100
$33.54 P/Share
|
|
Jun 24
2025
|
Brian Goff Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
38,277
+13.77%
|
-
|
|
Jun 24
2025
|
Tsveta Milanova Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
2,770
-9.59%
|
$91,410
$33.54 P/Share
|
|
Jun 24
2025
|
Tsveta Milanova Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+17.2%
|
-
|
Last 12 Months Summary
Buy / Acquisition
264K
Shares
From
14
Insiders
| Exercise of conversion of derivative security | 264K shares |
|---|
Sell / Disposition
142K
Shares
From
9
Insiders
| Open market or private sale | 142K shares |
|---|